Precision Biosciences Inc (DTIL) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Precision Biosciences reported revenue of $34.3M, down 50.1% from $68.7M the year before. Net income was -$45.7M (a -133.4% net margin), or -$3.56 per diluted share. Operating margin was -152.2%. Operating activities generated -$65.8M of cash, leaving -$65.9M of free cash flow. At fiscal year end, Precision Biosciences held $154.4M in total assets against $62.2M in total liabilities, including $110.8M of cash and equivalents.
Open the full interactive Precision Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Precision Biosciences Key Stats
| Share Price | $6.10 |
|---|---|
| Market Cap | $157.7M |
| Revenue YoY Growth | -50.1% |
| 52-Week Range | $3.57 – $9.28 |
| Shares Outstanding | 25.9 million (basic, 2026 Q2) |
Precision Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Operating Income | -$109.8M | -$39.4M | -$100.4M | -$43.7M | -$26.2M | -$52.1M |
| Pre-Tax Income | -$109.0M | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M |
| Income Tax | $23,000 | — | — | — | — | $0 |
| Net Income | -$109.0M | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M |
| Diluted EPS | -$62.70 | -$15.60 | -$38.10 | -$15.96 | $1.04 | -$3.56 |
Precision Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $13,000 | $34.2M | $10.8M | $0 |
| Net Income | -$21.8M | $20.1M | -$18.4M | -$32.7M |
| Diluted EPS | -$1.84 | $1.57 | -$0.75 | -$1.26 |
Precision Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $89.8M | $143.7M | $189.6M | $116.7M | $85.9M | $110.8M |
| Current Assets | $105.6M | $161.8M | $199.1M | $136.4M | $95.0M | $118.7M |
| Total Assets | $150.2M | $211.5M | $238.2M | $159.8M | $136.4M | $154.4M |
| Current Liabilities | $42.8M | $36.0M | $59.7M | $50.0M | $15.0M | $8.9M |
| Total Long-Term Debt | — | $2.5M | $22.2M | — | $22.3M | $22.4M |
| Total Liabilities | $105.7M | $120.3M | $177.7M | $140.9M | $80.0M | $62.2M |
| Shareholders' Equity | $44.4M | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M |
Precision Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$87.4M | -$10.9M | -$45.8M | -$84.1M | -$58.4M | -$65.8M |
| Cash From Investing | -$5.0M | -$5.8M | -$3.3M | $5.8M | -$215,000 | -$634,000 |
| Cash From Financing | $1.3M | $70.5M | $95.0M | $5.4M | $50.5M | $95.2M |
| Free Cash Flow | -$92.4M | -$15.9M | -$49.1M | -$86.1M | -$58.7M | -$65.9M |
Figures from Precision Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Precision Biosciences financials page for every line item.
Precision Biosciences Company Profile
| Ticker | DTIL |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Durham, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | May 21 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001357874 |
Frequently Asked Questions
What was Precision Biosciences' revenue in fiscal 2025?
Precision Biosciences (DTIL) reported revenue of $34.3M for fiscal 2025.
What is Precision Biosciences' annual revenue history?
Precision Biosciences' annual revenue by fiscal year: 2020: $24.3M; 2021: $115.5M; 2022: $25.1M; 2023: $48.7M; 2024: $68.7M; 2025: $34.3M.
What was Precision Biosciences' net income in fiscal 2025?
Precision Biosciences reported net income of -$45.7M for fiscal 2025.
What was Precision Biosciences' earnings per share (EPS) in fiscal 2025?
Precision Biosciences' diluted EPS was -$3.56 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Precision Biosciences generate in fiscal 2025?
Precision Biosciences generated -$65.9M of free cash flow in fiscal 2025.
What was Precision Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Precision Biosciences reported revenue of $0.
How much debt does Precision Biosciences have?
Precision Biosciences reported $22.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Precision Biosciences are outstanding?
Precision Biosciences reported a weighted average of 25.9 million basic shares outstanding in 2026 Q2.
What is Precision Biosciences' market cap?
Based on its latest closing price, Precision Biosciences (DTIL) has a market capitalization of about $157.7M.
When does Precision Biosciences' fiscal year end?
Precision Biosciences' fiscal year end, as registered with the SEC, is May 21.
Where is Precision Biosciences headquartered?
Precision Biosciences lists its business address in Durham, North Carolina in its SEC filings.
Precision Biosciences Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →